MedDataX Logo

Study Evaluation LXR-623 in Healthy Adults

NCT ID: NCT00379860

Last Updated: 2007-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating LXR-623 in Healthy Subjects

NCT00366522

Healthy
COMPLETED PHASE1

Study Evaluating LXR-623 in Healthy Japanese Adults

NCT00385489

Healthy
COMPLETED PHASE1

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects

NCT01284036

Healthy
COMPLETED PHASE1

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

NCT00789126

Healthy
COMPLETED PHASE1

Investigating the Safety of LEO 158968 in Healthy Volunteers

NCT05682352

Healthy Volunteers
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LXR-623

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Generally healthy adults.
* Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.

Exclusion Criteria

* A history or active presence of clinically important medical disease.
* Any metal implants or devices.
* Claustrophobia.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3201A1-101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
NCT01916850 COMPLETED PHASE1
Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses
NCT00909688 COMPLETED PHASE1
A Study of LY3871801 in Healthy Participants
NCT05222399 COMPLETED PHASE1
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
NCT06049095 RECRUITING PHASE1
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
NCT00820404 COMPLETED PHASE1
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants
NCT07271693 RECRUITING PHASE1
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
NCT05653323 COMPLETED PHASE1
Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects
NCT00796965 COMPLETED PHASE1
ANX-042 Healthy Volunteer Dose Escalation Study
NCT01638104 COMPLETED PHASE1
Study Evaluating the Safety of FXR-450 in Healthy Subjects
NCT00499629 COMPLETED PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
NCT06356259 TERMINATED PHASE1
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
NCT07039929 TERMINATED PHASE1
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
NCT03993704 COMPLETED PHASE1
A Safety Study of LY3372689 in Healthy Participants
NCT04106206 COMPLETED PHASE1
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
NCT06394167 COMPLETED PHASE1
A Study of RG7625 in Healthy Volunteers
NCT02295332 COMPLETED PHASE1
A Safety Study of LY3372689 Given By Mouth to Healthy Participants
NCT03819270 COMPLETED PHASE1
Phase 1 Study of ELX-02 in Healthy Adults
NCT03292302 COMPLETED PHASE1
A Safety Study of LY3526318 in Healthy Participants
NCT04682119 COMPLETED PHASE1
A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men
NCT05658107 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers
NCT01348165 TERMINATED PHASE1
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
NCT01162889 TERMINATED PHASE1
Phase 1 Study of ELX-02 in Healthy Adult Subjects
NCT03309605 COMPLETED PHASE1
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
NCT00447681 COMPLETED PHASE1
A Study to Assess the Safety of ARGX-109 in Healthy Volunteers
NCT06799416 COMPLETED PHASE1